We are live on ! Find out more
LPCN icon

Lipocine

28 hedge funds and large institutions have $1.64M invested in Lipocine in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.46% less ownership

Funds ownership: 0.9%0.45% (-0.46%)

13% less funds holding

Funds holding: 3228 (-4)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

23% less capital invested

Capital invested by funds: $2.12M → $1.64M (-$481K)

Holders
28
Holders Change
-4
Holders Change %
-12.5%
% of All Funds
0.62%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
5
Reduced
6
Closed
7
Calls
$7K
Puts
Net Calls
+$7K
Net Calls Change
+$10K
Name Holding Trade Value Shares
Change
Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
-$22K -3,468 Closed
Hudson Bay Capital Management
27
Hudson Bay Capital Management
Connecticut
-$17K -2,651 Closed
AFM
28
Anson Funds Management
Texas
-$8K -1,259 Closed
Bank of New York Mellon
29
Bank of New York Mellon
New York
-$5K -815 Closed
OAM
30
Oxford Asset Management
United Kingdom
-$5K -780 Closed
Simplex Trading
31
Simplex Trading
Illinois
-$324 -41 -87%
Wells Fargo
32
Wells Fargo
California
+$95 +12 New

LPCN Hedge Fund Activity: Q1 2020 in Review

28 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2020, worth a combined $1.64M — down 23% from $2.12M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of LPCN and 6 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 5 added.

The largest buyer was Ameriprise, adding an estimated $126K. The largest seller was Renaissance Technologies, cutting an estimated $757K.

  • 28 institutional investors held Lipocine (LPCN) as of Q1 2020, down from 32 in Q4 2019.
  • Funds reported $1.64M of Lipocine stock for Q1 2020, down 23% quarter-over-quarter.
  • 6 funds opened new Lipocine positions in Q1 2020 and 7 closed out, a net change of -1 holder.
  • The largest Lipocine buyer in Q1 2020 was Ameriprise, an estimated $126K added.
  • The largest Lipocine seller in Q1 2020 was Renaissance Technologies, an estimated $757K sold.

Based on aggregated 13F filings for Q1 2020.